#United States #New York #Gross Law Firm #MoonLake #MLTX

Alert for MoonLake Immunotherapeutics Shareholders

On December 11, 2025, The Gross Law Firm announced an important update for shareholders of MoonLake Immunotherapeutics, publicly traded as MLTX on NASDAQ. Investors who acquired shares during the designated class period, ranging from March 10, 2024, to September 29, 2025, are encouraged to register their information for potential involvement in a class action lawsuit.

Class Action Overview

The class action lawsuit accuses MoonLake Immunotherapeutics of issuing materially false and misleading statements, specifically concerning their primary drug candidate, SLK, and its relationship with another existing drug, BIMZELX. Allegations assert that:
1. Both SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F).
2. The unique structure of SLK, known as a Nanobody, is suggested not to confer any clinical advantage over BIMZELX's conventional monoclonal antibody structure.
3. Claims regarding SLK's enhanced tissue penetration have not been substantiated by clinical outcomes.
4. Prior positive representations concerning SLK's efficacy were, thus, fundamentally unsupported.

Important Deadlines

The law firm emphasizes the urgency regarding the lead plaintiff deadline set for December 15, 2025. Shareholders are encouraged to act quickly to register and have their information documented, as this could potentially lead to being appointed as a lead plaintiff. However, the firm clarifies that appointment is not a prerequisite for participating in any recovery that may arise from the class action.

Next Steps for Shareholders

Interested shareholders should promptly visit the provided link to register and get updates about the case lifecycle. Once registered, investors will benefit from a portfolio monitoring system that keeps them informed. The registration process ensures no cost or obligation to participants.

About The Gross Law Firm

The Gross Law Firm is recognized nationally for its dedication to holding corporations accountable for any actions that breach investor trust through deceitful practices. Their goal is to safeguard the rights of investors who have experienced losses due to false information or omissions from companies. Their commitment is to promote transparent business practices and good corporate governance.

For further inquiries, shareholders can contact The Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

As shareholders navigate this complex legal landscape, they are reminded of their rights and the available avenues for recovery under the class action provisions. Participation in this case not only represents a pursuit for justice but also serves as a pivotal step in ensuring that corporate accountability is upheld in the sector.

Timely action is crucial; the December deadline is approaching rapidly. Make sure to register before it's too late!